Tuesday, December 11, 2012

• Cramer's Top Stock Picks: IMGN ENG SGENat TheStreet (Tue, Dec 11)
• Cramer's Mad Money - Tupperware Is Fit For A Queen (12/10/12)at Seeking Alpha (Tue, Dec 11)

Monday, December 10, 2012

• [video] Buy Seattle Genetics on Pulback?at CNBC (Mon, Dec 10)
• Celldex Soars After Exciting Phase 2 Dataat Motley Fool (Mon, Dec 10)
• Seattle Genetics Announces Data from Investigator-Sponsored Trials of ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma at ASH Annual MeetingBusiness Wire (Mon, Dec 10)
• Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual MeetingBusiness Wire (Mon, Dec 10)
• Solid Data, More Studies Neededat Motley Fool (Mon, Dec 10)
• Celgene and More Big Movers in Healthcare on December 10, 2012at Investopedia (Mon, Dec 10)
• Seattle Genetics to test possible new Adcetris useAP (Mon, Dec 10)
• Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A at ASH Annual MeetingBusiness Wire (Mon, Dec 10)
• Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive Malignancies from Multiple Presentations at ASH Annual MeetingBusiness Wire (Mon, Dec 10)
• [video] Cramer's Six in 60: TripAdvisor, Monster Beverage & Moreat CNBC (Mon, Dec 10)
• Celldex Targeted Drug Benefits Patients With Aggressive Breast Cancerat TheStreet (Mon, Dec 10)

Sunday, December 9, 2012

• Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas (MTCL)Business Wire (Sun, Dec 9)
• Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in CD30-Positive Non-Hodgkin Lymphomas and Other Malignancies from Multiple Presentations at ASH Annual MeetingBusiness Wire (Sun, Dec 9)

Saturday, December 8, 2012

• Celldex Targeted Drug Benefits Patients With Aggressive Breast Cancerat TheStreet (Sat, Dec 8)

Thursday, December 6, 2012

• Seattle Genetics' Cancer Drug Highlighted at Medical Meetingat Minyanville (Thu, Dec 6)

Friday, November 30, 2012

• Celgene, NPS Pharmaceuticals, Amarin, J&J, Medivation Among Stocks to Watch in Decemberat Minyanville (Fri, Nov 30)

Tuesday, November 27, 2012

• Top 10 Biotechnology and Pharmaceutical Investing Interviews of 2012: Hepatitis C Therapies Drive Stock ValuesWall Street Transcript (Tue, Nov 27)
• Top 10 Biotechnology and Pharmaceutical Investing Interviews of 2012: Institutional Investor All-America Research Team Rising Star Matthew Roden at UBS Investment BankWall Street Transcript (Tue, Nov 27)

Monday, November 26, 2012

• Seattle Genetics drug gets new orphan drug reviewAP (Mon, Nov 26)
• Show Me The Money: ADC Revenue Payloads Miss The Markat Seeking Alpha (Mon, Nov 26)
• Seattle Genetics' T-cell lymphoma drug gets FDA orphan drug statusat bizjournals.com (Mon, Nov 26)
• Seattle Genetics Receives FDA Orphan Drug Designation for ADCETRIS® (Brentuximab Vedotin) in Mycosis FungoidesBusiness Wire (Mon, Nov 26)

Thursday, November 15, 2012

• 3 Biotechs Burning Cash to Keep the Lights Onat Motley Fool (Thu, Nov 15)

Add SGEN News to My Yahoo!